Dr. Chen Huang , Shenzhen Institute of Advanced Technology (SIAT) Chinese Academy of Sciences (CAS) , China
Dr. Chen Huang is an Associate Researcher at the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences. She earned her Ph.D. in 2018 from the University of the Chinese Academy of Sciences. Her primary research lies at the intersection of female reproductive endocrinology and metabolic diseases, focusing on how adverse intrauterine environments impact long-term offspring health. Dr. Huang has authored over 20 SCI-indexed papers and holds 18 published patents with one under review. She has played significant roles in national and regional projects funded by the NSFC and Shenzhen Innovation Commission. Her notable contributions include identifying novel peptides with therapeutic potential in NAFLD and TNBC, and exploring molecular mechanisms behind pregnancy complications. Her impactful work, especially on metabolitin (MTL) and chemerin/GPR1 signaling pathways, has earned recognition in high-impact journals like Journal of Hepatology. Dr. Huang’s commitment to translational research places her at the forefront of biomedical innovation in women’s health.
Publication Profile:
Scopus
Strengths for the Award:
Dr. Chen Huang exemplifies academic and scientific excellence through her impactful research in the fields of female reproductive endocrinology and metabolic diseases. Her contributions have led to meaningful advancements in understanding the molecular mechanisms that govern maternal-fetal health and associated disorders such as NAFLD, pregnancy complications, and cancer.
Key strengths include:
-
Scientific Innovation: She has identified and characterized novel peptide hormones such as metabolitin (MTL) and explored their therapeutic roles, a groundbreaking approach in targeting metabolic and oncological diseases.
-
High-Quality Publications: With around 20 SCI-indexed journal articles, including those in high-impact journals like Journal of Hepatology and Molecular Therapy – Oncolytics, her work is widely recognized in the scientific community.
-
Patent Portfolio: Dr. Huang has published 18 patents, with another under review, demonstrating her strong translational focus and commitment to real-world biomedical applications.
-
Research Leadership: She has successfully led multiple competitive national and regional research projects funded by the NSFC and Shenzhen Innovation Commission.
Areas for Improvement:
While Dr. Huang’s research output and contributions are impressive, certain enhancements could further elevate her global profile:
-
International Exposure: Engaging in more international collaborative projects or joint publications with global institutes could broaden the impact of her research.
-
Editorial and Professional Roles: Participation in editorial boards, peer review panels, or scientific committees would enhance her leadership presence in the scientific ecosystem.
-
Industry Engagement: Establishing collaborations with biotech or pharmaceutical industries could increase the translational value of her work and open pathways for clinical applications.
🎓 Education:
Dr. Chen Huang received her Ph.D. in 2018 from the University of the Chinese Academy of Sciences. Her doctoral research laid the foundation for her interest in female reproductive endocrinology and metabolic disorders, combining clinical insight with molecular research. Throughout her academic training, she focused on identifying the mechanistic links between endocrine disruptions during pregnancy and their long-term effects on offspring health. She has continually built upon this expertise through advanced training and interdisciplinary collaborations. Her educational background provided her with a robust understanding of molecular biology, endocrine physiology, and metabolic pathways, which she has applied in various research contexts—from liver disease to cancer biology. Her academic excellence was further highlighted by her early co-first authorship in high-impact journals during her Ph.D., demonstrating her ability to lead and innovate in collaborative research projects even in early stages of her career.
🧪 Experience:
Dr. Chen Huang is currently serving as an Associate Researcher at the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences. Since completing her Ph.D. in 2018, she has led and contributed to several key research projects, including those funded by the National Natural Science Foundation of China and the Shenzhen Science and Technology Innovation Commission. Her experience spans both basic and translational science, with an emphasis on hormonal regulation and metabolic diseases during pregnancy. She has collaborated with renowned scientists like Dr. Teng and Dr. Enkui Duan, contributing to the discovery of new peptide hormones such as metabolitin (MTL). Her professional experience is enriched by her ability to translate complex molecular findings into therapeutic strategies, especially in contexts like NAFLD and triple-negative breast cancer. With over 20 peer-reviewed SCI publications, her work reflects a consistent commitment to advancing biomedical research with clinical relevance.
🔬 Research Focus:
Dr. Chen Huang’s research focuses on the molecular underpinnings of female reproductive endocrinology and metabolic diseases, particularly within the context of pregnancy. She investigates how adverse intrauterine environments affect fetal development and contribute to long-term health issues in offspring. Her work explores key hormone-receptor interactions, such as the role of novel peptides (e.g., metabolitin) in liver disease and cancer. A major thread of her research also addresses the function of adipokines and their signaling pathways in pregnancy complications such as miscarriage and preeclampsia. Using both in vivo and in vitro models, she studies the regulatory mechanisms of trophoblast invasion, spiral artery remodeling, and immune cell interactions in the placenta. Her work integrates endocrinology, immunology, and developmental biology to identify new therapeutic targets. With an h-index of 12, she is recognized for her impactful publications and innovation in peptide-based treatments.
đź“š Publications Top Notes:
-
🧬 Metabolitin (MTL) as a GPRC6A ligand improves NAFLD – Journal of Hepatology, 2020 (Co-first author)
-
🧪 Peptide blocks chemerin/GPR1 signaling to inhibit TNBC growth – Molecular Therapy – Oncolytics, 2020 (First author)
-
🔍 Adipokine promotes placental trophoblast invasion and vascular remodeling – Am J Physiol-Endocrinol Metab, 2019 (Co-first author)
-
🔬 mTOR hypoactivity causes trophectoderm failure via lysosomal activation – Cell and Bioscience, 2023
Conclusion:
Dr. Chen Huang is a highly deserving candidate for the Best Researcher Award. Her research contributions stand out in both innovation and societal impact, especially in the crucial domains of reproductive health and metabolic diseases. With a consistent publication record, numerous patents, and demonstrated research leadership, she is poised to make even greater scientific contributions in the years ahead. Recognizing her with this a